A COMPARISON OF DAILY VS TWICE-DAILY INSULIN GLARGINE

每日与每日两次甘精胰岛素的比较

• 批准号: 7606853
• 负责人: MARK R BURGE
• 金额: $ 0.56万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606853
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Daily; Funding; Grant; Hour; Injection of therapeutic agent; Institution; Insulin; Research; Research Personnel; Resources; Serum; Source; United States National Institutes of Health; glargine; glycemic control

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this study is to demonstrate if twice-daily subcutancous injections of insulin glargine will produce higher serum insulin concentrations between 20-24 hours after the first injection and therefore provide better glycemic control.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是证明每日两次皮下注射甘精胰岛素是否会在首次注射后20-24小时内产生更高的血清胰岛素浓度，从而提供更好的血糖控制。